IRLAB Therapeutics
IRLAB is granted additional patent for drug candidate pirepemat that expands its patent protection
Gothenburg, Sweden, December 12, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted a new patent in Europe related to both a new salt of the drug candidate pirepemat and the process for its preparation. This new patent, which covers the active pharmaceutical ingredient (API) used in the ongoing clinical Phase IIb development, has also been granted in the strategically important markets Japan and China.
“With this patent, IRLAB is adding to the already strong patent protection for one of its lead programs, pirepemat, providing further exclusivity and adding to the value of the pirepemat program. This is a key factor in partnering and commercialization discussions,” said Gunnar Olsson, CEO, IRLAB.
Pirepemat has the potential to become the first treatment in a new class of drugs designed to reduce falls, and thus fall injuries, in people living with Parkinson’s disease. Pirepemat has previously been granted composition of matter patents providing pirepemat exclusivity in the major markets; China, EU, Japan, and the US. The recently granted additional patent, covering the salt of the drug used in the ongoing clinical development, is predicted to expire in 2038. With the potential grant of supplementary protection certificates (SPCs) or patent term extension (PTE), exclusivity can potentially reach into the early 2040s.
For further information, please contact:
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
| Datum | 2023-12-12, kl 07:00 |
| Källa | MFN |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.